AIM-quoted Summit, which is also listed on the Nasdaq in New York, tested compounds from its DDS-04 series on mice which had been infected with the two conditions.
The DDS-04 compound cured the mice with sepsis, while it ‘significantly reduced’ the bacterial burden in the lungs in those with pneumonia.
The data build on previous preclinical research in urinary tract infections and suggest that DDS-04 has potential to treat Enterobacteriaceae infections in all three key infection sites: urinary tract, bloodstream and lung.
It is the latter two where there is the greatest unmet patient need, Summit said.
No new antibiotics this century
“There is a great need to advance truly differentiated treatments for Gram-negative bacteria, where there have been no new classes of antibiotics discovered since the last century,” said Summit’s president of R&D, David Roblin.
“In particular, the rise of untreatable and hard to treat Enterobacteriaceae infections is a frightening prospect.
“DDS-04 aligns with our strategy of targeting pathogenic bacteria and seeking to preserve patients’ good bacteria known to play an important role in overall patient health.”
In early afternoon trading, Summitt shares gqained 3.2% at 24.50p.
-- Updates share price --